drugset
drugset / Trial / NCT01771679

Safety Study of Bone Marrow Derived Stem Cells on Patients With Cutaneous Photoaging

NCT01771679 ↗

Phase 1/2 Unknown 29 enrolled Stemedica Cell Technologies, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether a one-time injection of allogeneic mesenchymal bone marrow cells is safe and beneficial in the treatment of photodamage on the face.

Timeline

Start
2015-07-01
Primary completion
2024-04-30
Completion
2024-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Allogeneic Mesenchymal Bone Marrow Cells Cell therapy 0.5 cells/kg Intravenous
Subject Allogeneic Mesenchymal Bone Marrow Cells Cell therapy 1 cells/kg Intravenous
Subject Allogeneic Mesenchymal Bone Marrow Cells Cell therapy 1.5 cells/kg Intravenous

Indications

chronic actinic dermatitis